Halozyme Therapeutics, Inc. · NASDAQ:HALO

Connaughton Bernadette received 3,796 Halozyme Therapeutics, Inc. shares as an award (Form 4/A)

Traded May 5, 2026 · Filed Oct 8, 2026

On May 5, 2026, Connaughton Bernadette (Director) received 3,796 Halozyme Therapeutics, Inc. shares as an award, leaving 42,294 shares. Filed Oct 8, 2026 (Form 4/A).

Awarded
3,796 shares
Holding after
42,294 shares
Trading plan
No
Role
Director

The filing in full

DateSecurityTransactionSharesPriceHolding afterOwnership
May 5, 2026Common StockAward3,79642,294Direct

Source

View original at SEC

Related